DECIPHERA PHARMACEUTICALS IN (DCPH)
US24344T1016 - Common Stock
DCPH gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. DCPH has a great financial health rating, but its profitability evaluates not so good. DCPH is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
DCPH had negative earnings in the past year.
DCPH had a negative operating cash flow in the past year.
DCPH had negative earnings in each of the past 5 years.
DCPH had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
DCPH has a Return On Assets of -41.16%. This is comparable to the rest of the industry: DCPH outperforms 59.73% of its industry peers.
DCPH has a better Return On Equity (-55.55%) than 64.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.16% | ||
| ROE | -55.55% | ||
| ROIC | N/A |
ROA(3y)-50.14%
ROA(5y)-44.56%
ROE(3y)-68.79%
ROE(5y)-58.11%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DCPH has a better Gross Margin (97.72%) than 97.95% of its industry peers.
DCPH's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for DCPH so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 97.72% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.59%
GM growth 5YN/A
2. Health
2.1 Basic Checks
DCPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DCPH has more shares outstanding
The number of shares outstanding for DCPH has been increased compared to 5 years ago.
DCPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
DCPH has an Altman-Z score of 5.39. This indicates that DCPH is financially healthy and has little risk of bankruptcy at the moment.
DCPH's Altman-Z score of 5.39 is amongst the best of the industry. DCPH outperforms 80.38% of its industry peers.
DCPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.39 |
ROIC/WACCN/A
WACC9.27%
2.3 Liquidity
A Current Ratio of 3.80 indicates that DCPH has no problem at all paying its short term obligations.
DCPH has a Current ratio of 3.80. This is comparable to the rest of the industry: DCPH outperforms 42.66% of its industry peers.
A Quick Ratio of 3.59 indicates that DCPH has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.59, DCPH is in line with its industry, outperforming 41.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.8 | ||
| Quick Ratio | 3.59 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 10.20% over the past year.
The Revenue has grown by 21.87% in the past year. This is a very strong growth!
DCPH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 57.16% yearly.
EPS 1Y (TTM)10.2%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q10%
Revenue 1Y (TTM)21.87%
Revenue growth 3Y57.16%
Revenue growth 5YN/A
Revenue growth Q2Q32.88%
3.2 Future
The Earnings Per Share is expected to grow by 17.94% on average over the next years. This is quite good.
The Revenue is expected to grow by 26.51% on average over the next years. This is a very strong growth
EPS Next Y3.71%
EPS Next 2Y11.41%
EPS Next 3Y17.43%
EPS Next 5Y17.94%
Revenue Next Year24.46%
Revenue Next 2Y26.24%
Revenue Next 3Y31.37%
Revenue Next 5Y26.51%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for DCPH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DCPH. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
DCPH's earnings are expected to grow with 17.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.41%
EPS Next 3Y17.43%
5. Dividend
5.1 Amount
DCPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
DECIPHERA PHARMACEUTICALS IN
NASDAQ:DCPH (5/2/2024, 11:24:51 AM)
25.36
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.05B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.16% | ||
| ROE | -55.55% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 97.72% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.8 | ||
| Quick Ratio | 3.59 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)10.2%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y3.71%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)21.87%
Revenue growth 3Y57.16%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y